위축성 위염 혹은 위암에 미치는 프로톤펌프억제제의 영향: Unsafe 측면 = Special Review : Concerns on Atrophic Gastritis and Neoplasia: Unsafe Perspective

다국어 초록 (Multilingual Abstract)

Proton-pump inhibitors (PPI) have important roles in the management of acid-related disorders, especially gastro-esophageal reflux disease and peptic ulcer disease. They are considered safe, but some side effects, such as oxyntic cell hyperplasia, glandular cysts, hypergastrinemia and fundic gland polyps, are also reported. Long-term PPI administration in Helicobacter pylori (H. pylori) positive subjects promotes a shift from antral to corpus-predominant gastritis. The shift leads to corpus atrophy eventually that is known predisposing factor of gastric adenocarcinoma. It is recommended that patients being considered for long-term PPI therapy should be tested for H. pylori infection. And if present, H. pylori eradication should be preceded to PPI administration. Also, long-term PPI administration can cause enterochromaffin-like cell hyperplasia. Although the underlying mechanism and pathogenesis are not yet fully understood, it is possible that long-term PPI administration can promote the development of gastric carcinoid tumor. Therefore, to minimize the side effects, it should be used in adequate dose for a precise duration. (Korean J Med 2011;81:6-10)

참고문헌 (Reference)

1 Ekman L, "Toxicological studies on omeprazole" 108 : 53-69, 1985

2 Larsson H, "Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion. Studies with omeprazole and ranitidine in intact and antrectomized rats" 95 : 1477-1486, 1988

3 Vicari JJ, "The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease" 115 : 50-57, 1998

4 Targownik LE, "The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs" 134 : 937-944, 2008

5 Wang TC, "Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer" 118 : 36-47, 2000

6 Raghunath AS, "Review article: the long-term use of proton-pump inhibitors" 22 (22): 55-63, 2005

7 Robinson M, "Review article. current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia" 13 (13): 5-10, 1999

8 Kuipers EJ, "Proton pump inhibitors and gastric neoplasia" 55 : 1217-1221, 2006

9 Weston AP, "Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma" 95 : 387-394, 2000

10 Dawson R, "Omeprazole in oesophageal reflux disease" 356 : 1770-1771, 2000

11 Hawkey CJ, "Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group" 338 : 727-734, 1998

12 McColl KE, "Omeprazole and accelerated onset of atrophic gastritis" 118 : 239-, 2000

13 Pounder RE, "Omeprazole and accelerated onset of atrophic gastritis" 118 : 238-239, 2000

14 Maton PN, "Omeprazole" 324 : 965-975, 1991

15 Vaananen H, "Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study" 15 : 885-891, 2003

16 Hagiwara T, "Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with Helicobacter pylori" 60 : 624-630, 2011

17 Klinkenberg-Knol EC, "Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa" 118 : 661-669, 2000

18 Lundell L, "Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group" 117 : 319-326, 1999

19 Jalving M, "Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy" 24 : 1341-1348, 2006

20 Kuipers EJ, "Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety" 90 : 1401-1406, 1995

21 Bateson MC, "Hypergastrinaemia with long-term omeprazole treatment" 13 : 440-441, 1999

22 Correa P, "Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention" 52 : 6735-6740, 1992

23 Fox JG, "Helicobacter pylori-associated gastric cancer in INS-GAS mice is gender specific" 63 : 942-950, 2003

24 Uemura N, "Helicobacter pylori infection and the development of gastric cancer" 345 : 784-789, 2001

25 el-Omar EM, "Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease" 109 : 681-691, 1995

26 Peek RM Jr, "Helicobacter pylori and gastrointestinal tract adenocarcinomas" 2 : 28-37, 2002

27 Yang HB, "H. pylori eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using long-term esomeprazole" 104 : 1642-1649, 2009

28 El-Zimaity HMT, "Geographic differences in the distribution of intestinal metaplasia in duodenal ulcer patients" 96 : 666-672, 2001

29 Garcia Rodriguez LA, "Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK" 55 : 1538-1544, 2006

30 Stolte M, "Fundic gland polyps: a rare, innocuous, and reversible disturbance" 105 : 1590-1591, 1993

31 Havu N, "Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion" 35 (35): 42-55, 1986

32 Safholm C, "Effect of 7 years' daily oral administration of omeprazole to beagle dogs" 55 : 139-147, 1994

33 Malfertheiner P, "Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report" 56 : 772-781, 2007

34 Kuipers EJ, "Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial" 53 : 12-20, 2004

35 Orlando LA, "Chronic hypergastrinemia: causes and consequences" 52 : 2482-2489, 2007

36 Poynter D, "Changes in the gastric mucosa of the mouse associated with long lasting unsurmountable histamine H2 blockade" 27 : 1338-1346, 1986

37 Kuipers EJ, "Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication" 334 : 1018-1022, 1996

38 Hirai I, "Assessment of East Asian-type cagA-positive Helicobacter pylori using stool specimens from asymptomatic healthy Japanese individuals" 58 : 1149-1153, 2009

39 Waldum HL, "Antiulcer drugs and gastric cancer" 50 (50): S39-S44, 2005

40 Chey WD, "American College of Gastroenterology guideline on the management of Helicobacter pylori infection" 102 : 1808-1825, 2007